Julie Samyde1, Pierre Petit2, Dominique Hillaire-Buys1,3, Jean-Luc Faillie4,5. 1. Department of Medical Pharmacology and Toxicology, CHU Montpellier University Hospital, Montpellier, France. 2. Department of Psychiatry, CHU Montpellier University Hospital, Montpellier, France. 3. INSERM U1058, Faculty of Medicine, University of Montpellier, Montpellier, France. 4. Department of Medical Pharmacology and Toxicology, CHU Montpellier University Hospital, Montpellier, France. jl-faillie@chu-montpellier.fr. 5. Laboratory of Biostatistics, Epidemiology and Public Health (EA 2415), Faculty of Medicine, University of Montpellier, Montpellier, France. jl-faillie@chu-montpellier.fr.
Abstract
RATIONALE: Several case-reports suggest that the use of quinolones may increase the risk of psychiatric adverse reactions such as suicidal behaviors. OBJECTIVES: The aim of this study is to investigate whether there is a safety signal for quinolone-related suicidal behaviors in a global adverse drug reactions database. METHODS: All antibiotic-related adverse reactions were extracted from VigiBase, the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database. Disproportionality analyses were performed to investigate the association between reports of suicidal behavior and exposure to quinolones, in comparison with other antibiotics. RESULTS: From December 1970 through January 2015, we identified 992,097 antibiotic-related adverse reactions. Among them, 608 were quinolone-related suicidal behaviors including 97 cases of completed suicides. There was increased reporting of suicidal behavior (adjusted reporting odds ratios [ROR] 2.78, 95 % CI 2.51-3.08) with quinolones as compared to other antibiotics. Candidate mechanisms for quinolone-induced suicidal behaviors include GABAA antagonism, activation of NMDA receptors, decreased serotonin levels, oxidative stress, and altered microRNA expressions. CONCLUSIONS: We found a strong safety signal suggesting an increased risk of suicidal behaviors associated with quinolone use. Plausible psychopharmacological mechanisms could underlie this association. Further investigations are urgent to confirm and better understand these findings.
RATIONALE: Several case-reports suggest that the use of quinolones may increase the risk of psychiatric adverse reactions such as suicidal behaviors. OBJECTIVES: The aim of this study is to investigate whether there is a safety signal for quinolone-related suicidal behaviors in a global adverse drug reactions database. METHODS: All antibiotic-related adverse reactions were extracted from VigiBase, the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database. Disproportionality analyses were performed to investigate the association between reports of suicidal behavior and exposure to quinolones, in comparison with other antibiotics. RESULTS: From December 1970 through January 2015, we identified 992,097 antibiotic-related adverse reactions. Among them, 608 were quinolone-related suicidal behaviors including 97 cases of completed suicides. There was increased reporting of suicidal behavior (adjusted reporting odds ratios [ROR] 2.78, 95 % CI 2.51-3.08) with quinolones as compared to other antibiotics. Candidate mechanisms for quinolone-induced suicidal behaviors include GABAA antagonism, activation of NMDA receptors, decreased serotonin levels, oxidative stress, and altered microRNA expressions. CONCLUSIONS: We found a strong safety signal suggesting an increased risk of suicidal behaviors associated with quinolone use. Plausible psychopharmacological mechanisms could underlie this association. Further investigations are urgent to confirm and better understand these findings.
Entities:
Keywords:
Adverse drug reactions; Psychopharmacology; Quinolones; Suicidal behaviors; Suicide
Authors: Peter G M van der Heijden; Eugène P van Puijenbroek; Stef van Buuren; Jacques W van der Hofstede Journal: Stat Med Date: 2002-07-30 Impact factor: 2.373
Authors: Michael Maes; Piotr Galecki; Yong Seun Chang; Michael Berk Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2010-05-12 Impact factor: 5.067
Authors: Antoine Pariente; Fleur Gregoire; Annie Fourrier-Reglat; Françoise Haramburu; Nicholas Moore Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Luiza Hoehl Loureiro Alves Barbosa; Alice Ramos Oliveira Silva; Ana Paula D'Alincourt Carvalho-Assef; Elisangela Costa Lima; Fabricio Alves Barbosa da Silva Journal: Front Pharmacol Date: 2022-09-20 Impact factor: 5.988
Authors: Yuyao Guan; Lei Ji; Lei Zheng; Jing Yang; Yizhuo Qin; Ning Ding; Ting Miao; Xuemei Liu Journal: Front Pharmacol Date: 2022-10-04 Impact factor: 5.988